⏱ 11 min read
A Note from the Editor
This medical case study examines the severe financial toxicity and the actual HER2 positive breast cancer cost under U.S. Medicare compared to South Korea’s National Health Insurance, highlighting the poignant phenomenon of medical migration. This piece is about an immigrant family. Not one I know directly, but a story pieced together from people in the surrounding circle. An ordinary Korean American family. It’s a story that could read as quiet grief, or it could read as something close to luck (depending on how you turn it) because they at least had another option to fall back on. But when a lifetime of work toward a dream gets interrupted by something nobody planned for, and the dream itself has to be set down, the story leans toward the sadder side.
They were a hardworking couple. They never stopped, day after day. That isn’t unusual for an immigrant family, of course. They were one of many. They came to America without a word of English, looking for a better chance for themselves and a better life for their children.
The Card on the Counter
A Medicare card sits on the counter of a closing Korean restaurant in suburban America. The husband opened the envelope a week ago and left the card right there, next to the register. Every morning since, he’s been drinking his coffee beside it. His wife isn’t here. She’s been in Korea for seven months. He’s closing the restaurant alone. Last day of service is next week.
The couple came to the United States in 1990. They were thirty years old. They built one Korean restaurant and spent thirty-five years inside it. Both children went through college on what the restaurant earned. They became American citizens in 1998. The framed photo of his wife raising her hand at the swearing-in ceremony hung on their living room wall for twenty-seven years. Last week he packed it into a cardboard box in the kitchen.
They had dropped private health insurance years before. The combined monthly premium had passed three thousand dollars and was about to hit four. A full month of restaurant profit, gone to a single bill. His wife said it out loud first. “We just have to stay healthy until sixty-five.” Medicare. The promise every American gets at age sixty-five. They cancelled the policy and bet the next ten years on staying healthy. The years passed without incident. Until the first week of January 2025.
The HER2 Breast Cancer Cost That Forced the Decision
His wife felt a hard lump in her right breast on a Sunday. With no insurance, she paid cash at a local imaging clinic. Diagnostic mammogram. Ultrasound. Breast MRI. Image-guided biopsy. Pathology. Immunohistochemistry. HER2 FISH testing. Staging CT and PET. The first oncology visit. By the time the workup was done, the bills came to more than fifteen thousand dollars. The couple paid out of restaurant operating cash.
The oncologist was a calm man. He turned the screen toward them and pointed at the tumor. About 3.5 centimeters. Two lymph nodes under her arm tested positive. Stage IIIa. The line that mattered was the last one on the report. HER2 positive.
His wife’s face tightened. The oncologist moved quickly. “The good news is, HER2 positive has a drug that works very well.” He wrote two names on a whiteboard: Herceptin and Perjeta.
About 15 to 20 percent of breast cancer patients in the United States have tumors that overexpress a protein on the cancer cell surface called HER2 (human epidermal growth factor receptor 2). The protein sends rapid growth signals, which is why HER2 positive tumors grow faster and recur more often. Hormonal therapies like tamoxifen and aromatase inhibitors don’t work on HER2 positive disease, but drugs that target the HER2 protein itself work very well. Before Herceptin came out in 1998, HER2 positive was one of the worst diagnoses in breast cancer. After Herceptin, the picture changed. With full standard treatment, the five-year survival rate for Stage II HER2 positive disease runs in the 90 percent range. For Stage IIIa, it sits around 80 percent. Even with positive lymph nodes, this is a curable cancer.
The oncologist sketched out the treatment plan on a sheet of paper. Six cycles of pre-surgical chemotherapy combined with both targeted drugs to shrink the tumor. Then surgery to take out what was left. Then a year of targeted therapy after surgery to keep it from coming back. The protocol has a name: TCHP. Taxane (paclitaxel), Carboplatin, Herceptin, Perjeta. He added one more sentence at the end. “The drugs are very expensive.”
Herceptin (trastuzumab) is a monoclonal antibody that binds directly to the HER2 protein and shuts down its growth signal. The FDA approved it in 1998. The U.S. list price runs about $5,800 per infusion (every three weeks). A full course of seventeen infusions over one year totals roughly $100,000. Perjeta (pertuzumab) is a second HER2 antibody approved in 2012. It binds a different spot on the HER2 protein, so when it’s given alongside Herceptin the two drugs hit the target from two angles. The U.S. list price runs about $5,500 per infusion. Together, one year of Herceptin and Perjeta costs around $200,000 at U.S. list price, roughly 290 million Korean won. The APHINITY trial’s long-term follow-up showed that adding Perjeta to Herceptin cut the risk of death by 17 percent overall, and by 21 percent in patients with positive lymph nodes. One in five patients who would have died, alive instead.
The oncologist kept talking. The husband stopped following the words. He was running numbers in his head. Drugs alone, $200,000 a year. Surgery, around $50,000. Radiation, $30,000. Chemo, imaging, oncology visits, blood work, supportive care: another $50,000 to $100,000. Uninsured, the HER2 breast cancer cost in the United States for one year of full treatment would push the bills to $350,000 to $400,000. Five hundred million to five hundred eighty million won. The couple didn’t have that money. Nothing in the restaurant came close.
His second calculation was Medicare. Medicare started for them in January 2026, exactly twelve months away. Wait twelve months and Medicare solves it. That was the sentence the couple had been carrying in their heads for ten years. Sitting in the oncologist’s office for the first time, the husband actually looked at how Medicare worked.
Original Medicare splits into Part A (inpatient) and Part B (outpatient). Part B covers oncology visits, imaging, and infused cancer drugs like Herceptin and Perjeta. Patients pay a monthly premium ($202.90 in 2026), an annual deductible of $283, and then 20 percent of the Medicare-allowed amount for each service. Medicare picks up the other 80 percent. Hospitals and oncologists who accept Medicare assignment (almost all do) cannot bill the patient for the difference between their list price and the Medicare-allowed amount, so the patient never pays the gap. But here is the line that decides everything. That 20 percent has no annual ceiling. If the Medicare-allowed amount for one year of Herceptin and Perjeta runs near $200,000, the patient owes $40,000. Surgery, radiation, imaging, infusion fees: each carries another 20 percent on top. Medicare Supplement (Medigap) insurance covers that 20 percent, but it costs an additional monthly premium and almost always requires enrollment within six months of turning 65. Once cancer is on the record, underwriting almost always denies you, or quotes a premium higher than the original ACA plan the couple had cancelled.
The husband ran the numbers again. Twenty percent of $200,000 in drugs is $40,000. Add 20 percent on surgery, radiation, imaging, oncology visits, hospital admissions. Even with Medicare in hand, the annual HER2 breast cancer cost would run $70,000 to $90,000 out of pocket. About 100 million to 130 million won. Every year. And his wife would be too sick to run the restaurant for most of that year, so the business income would drop to zero. Medigap was off the table. On Medicare, the HER2 breast cancer cost stayed structurally unfixable. The husband’s grip tightened on the chair arm. A single cancer diagnosis was enough to take everything thirty-five years had built. Thirty-five years of paying taxes had bought them this much protection. No more.
They walked out without a word. He started the car in the parking lot, then sat with his hands on the wheel. He spoke first. “Let’s go to Korea.”
From the Decision to the Plane
That night the calls began. A cousin worked as a nurse at a major Seoul university hospital. She introduced them to the hospital and an oncologist there. Their adult daughter, working in San Francisco, started reading through Korea’s National Health Insurance rules and the Rare Cancer Co-payment Reduction program. Their son in Boston handled travel logistics and confirmed the first outpatient appointment in Seoul. Within a week, the family had enough information to act.
The Korean oncologist’s reply came back fast. Same diagnosis. Same protocol: TCHP for six cycles before surgery, then surgery, then targeted therapy for a year afterward. With the rare cancer co-payment program covering the patient share at 5 percent on most items, plus partial reimbursement on Perjeta in the pre-surgical phase at 30 percent, the HER2 breast cancer cost in Korea, by contrast, came in at 10 to 15 million won for a full year. Roughly 7,000 to 11,000 dollars. About one-tenth of what the American Medicare estimate would have cost them.
U.S. Medicare vs. Korea NHI: Cancer Drug Out-of-Pocket Cost Comparison (2026)
The table below details the massive structural gap in patient cost-sharing for essential oncology lines between the United States and South Korea, based on 2026 public data.
| Antineoplastic Drug (Brand Name) | U.S. Annual List Price | U.S. Medicare Patient (20% Coinsurance) | Korea NHI Patient (Rare Cancer Program 5%) |
|---|---|---|---|
| Herceptin + Perjeta (Trastuzumab + Pertuzumab) |
~$200,000 | ~$40,000 / year | ~$10,000 (30% partial on Perjeta pre-op) |
| Keytruda (Pembrolizumab) |
~$200,000 | ~$40,000 / year | ~$10,000 / year |
| Enhertu (Trastuzumab Deruxtecan) |
~$156,000 | ~$31,200 / year | ~$7,800 / year |
| Kymriah (Tisagenlecleucel) |
$475,000 | Inpatient DRG / Variable | ~$23,750 (Max ceiling limits apply) |
His wife flew to Seoul that June. She rented a small condo in an outer Seoul neighborhood. Korean home prices had climbed too high. Even after selling everything in the United States, the couple couldn’t afford a small apartment in Seoul. Renting was the only option. Selling the American assets meant they wouldn’t be moving back. Both adult children were settled in the United States. Their parents would visit when they could. Moving back to America to live was no longer an option.
His wife registered for the rare cancer program at her first Seoul appointment in July. She held the certificate in her hands for a long time before she got up to leave. On the phone with her husband that night, she said it didn’t feel real that the same illness could come with two completely different prices. The first cycle of TCHP started in August. The second in September. The third in October. By November, imaging showed the tumor had shrunk to half its starting size. The oncologist scheduled the final pre-surgical cycle for December and surgery for February 2026.
While the Korean treatment moved forward, the husband closed things down in America one piece at a time. Negotiating the lease transfer. Selling kitchen equipment. Saying goodbye to regulars who had been eating there for two decades. Video calls with the children to let them know what was happening. The last day of service landed on the final week of January 2026.
🎨 AI-generated illustration
Same drugs, same manufacturer, three very different prices on three different shelves.
January 2026: The Card Arrived
The Medicare card came in the first week of the new year. The couple had been waiting for this card for ten years. The husband held it for a moment and ran the math one more time. Twenty percent on Part B, no ceiling. If his wife had stayed in America and faced the HER2 breast cancer cost on Medicare, the family would have paid $70,000 to $90,000 in the first year, around 100 million to 130 million won. That figure didn’t include the lost income from a closed restaurant. Everything they had built over thirty-five years would have been gone.
He set the card on the counter and left it there. He didn’t put it back in the envelope. He didn’t move it to his wallet. It was the safety net the couple had quietly held onto for a decade, and the day it arrived was the day they confirmed it wasn’t a safety net at all. It was half a net. His wife was already in Korea. It almost felt like relief.
The Same Canyon, Different Drugs
Herceptin and Perjeta aren’t unusual. Enhertu (trastuzumab deruxtecan), used for HER2 positive breast and gastric cancer in second-line settings, runs about $13,000 per cycle in the United States. Keytruda (pembrolizumab), the immunotherapy drug used in triple-negative breast cancer, melanoma, lung cancer, and many others, costs roughly $11,712 per infusion. A full year is about $200,000. Tagrisso (osimertinib), an oral EGFR inhibitor for non-small cell lung cancer, runs over $18,000 a month even though it’s a daily pill. Kymriah (tisagenlecleucel), a CAR-T cell therapy for B-cell leukemia and lymphoma, costs $475,000 for one infusion.
In Korea, all of these drugs are covered by National Health Insurance, and patients on the rare cancer program pay around 5 percent. Same drug. Same manufacturer. A gap of 80 to 100 times the price, depending on which government is buying.
Same molecule, same manufacturer. The price tag changes when the buyer changes.
Financial Toxicity
American oncology has a clinical term for what happens to patients in this situation. Financial toxicity. Not a side effect of the drug. A side effect of the drug’s price. The treatment keeps the patient alive while it takes apart the family’s savings, home, and retirement. Survey work from KFF and the American Cancer Society shows that a substantial share of cancer patients in the United States spend down savings, take on debt, downsize the house, or declare bankruptcy during treatment. American life expectancy runs lower than other wealthy countries partly because of this. Not because the drugs don’t exist. Because patients can’t reach the drugs that do exist. The HER2 breast cancer cost gap between the United States and Korea is one example among many. The same Herceptin the Korean government negotiates and pays for at a discount is the Herceptin the U.S. government buys close to list price. That difference decides where a family’s burden gets sent.
The Last Day at the Restaurant
The husband closes the restaurant next week. Thirty-five years are folding into boxes. The framed citizenship photo from 1998 went into the last box, beside a stack of old menus and the cash register key. He had believed that being an American meant nothing in his life would be missing. He worked thirty-five years on the strength of that belief. The same thirty-five years that didn’t stop the medical bill from settling on the only thing he had built. He has accepted that this is how it ends. The plane ticket to Seoul is for the second week of February.
He picks up the Medicare card from the counter and puts it in the last box, on top of the citizenship photo. He can’t use it in Korea. He doesn’t throw it out. The card was what he had been waiting 35 years for. He carries it across the Pacific anyway, into a country where it’ll sit in a drawer for the rest of his life.
Recommended Medical Economics Case Studies:
- U.S. Healthcare Spending versus Outcomes: Real-world Analysis
- Health Insurance Navigation and Choices After Age 50
Thanks for reading. Take care of yourself. Nobody else will do it for you.
Wilbur P is the editor of Manclub, leading coverage across health and life. His work is research-driven and built on primary sources a reader can verify – written for men in the second half of life who would rather know than believe. Based in Florida, still learning and still in the fight. Corrections, questions, story tips: [email protected].